Health

Nutriband seeks dual listing as it nears market launch for fentanyl patch

Nasdaq-listed pharma company seeks Upstream listing ahead of FDA approval for its Aversa-based abuse deterrent patches

Gareth Sheridan, founder and chief executive, Nutriband: ‘As of today, our market cap is maybe a third of what I expect our gross profit to be in a year or two.’ Picture: Vanja Savic